Levetiracetam in Autistic Children: An Open-Label Study

Rugino, Thomas A.; Samsock, Teresa C

doi:10.1097/00004703-200208000-00006

Cited by 106 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levetiracetam is an anticonvulsant that is associated with a number of psychiatric side effects, which include new-onset mood and anxiety symptoms, but rarely, psychotic symptoms [7][8][9]. A previous study in 288 epileptic patients using levetiracetam showed adverse psychiatric side effects in 37% of the patients, which included poor seizure control, mental retardation, and impulsivity [10].…”

Section: Discussionmentioning

confidence: 99%

Relationship of levetiracetam and obsessive-compulsive disorder: a case report

Çökmüş

Aşçıbaşı

Öztekin

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Relationship of levetiracetam and obsessive-compulsive disorder: a case report

Çökmüş

Aşçıbaşı

Öztekin

et al. 2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

“…Levetiracetam was effective in reducing hyperactivity, impulsivity, mood instability and aggression ( 183 ). In a controlled double blind study of this antiepileptic medication no improvement was noted in a wide range of symptoms found in this population ( 184 ).…”

Section: Anticonvulsantsmentioning

confidence: 81%

Autism Spectrum Disorder

Realmuto

2016

The Medical Basis of Psychiatry

View full text Add to dashboard Cite

This chapter identifi es the biological underpinnings, phenomenology, assessment and medical treatment of Autism Spectrum Disorder, a complex neurodevelopmental disorder. Basic science has made great strides in identifying the brain pathology of autism at various levels of scrutiny. This chapter reviews genetic, molecular, histological, anatomical and epidemiological levels of the disorder. Also, new assessment technologies have come on line to provide greater clarity in what collection of observations should be called autism and what would not. Although interventions that alter the newly identifi ed pathophysiological processes are yet to be formulated, approaches to treatment that fail to take into account the current scientifi c evidence of the causes of autism can and should be avoided. The chapter describes an orientation to autism from the perspective of the scientifi c literature to provide a foundation for clinical decision-making for the practitioner. IntroductionHow we evaluate, diagnose and treat autism is changing rapidly. Diagnostic and Statistical Manual 5 essentially eliminates autism as a discrete diagnostic entity and consistent with other neurodevelopmental disorders creates a continuum ( 1 ). Autism Spectrum Disorder (ASD) is one of twenty six diagnostic codes collected under the larger rubric of neurodevelopmental disorders in the American Psychiatric Association's newest diagnostic compendium. The diversity of disorders included span intellectual disability, Attention Defi cit Hyperactivity Disorder as well as learning disorders and motor disorders including Tic disorders.ASD can be plotted along a continuum of the essential ingredients of the original concept, now sixty years old, of Kanner's Autistic Disturbances of Affective Contact ( 2 ). Defi cits of emotional reciprocity and nonverbal communication and the narrow interests of the individual with autism remain. The distinction for DSM-5 from its predecessor is the constriction of the richness of the menu of criteria.Left as historical footnotes are the archaic views of causes now replaced by rich and exciting scientifi c data. This growing body of empirical research quickly moves the frontier of our understanding of the disorder and re-defi nes the medical basis of ASD. This chapter discusses some of the newer studies that have implications for our medical approach to the syndrome. Going forward, new research will need to validate whether fi ndings from studies of a forme fruste or lesser variants are equally relevant to its most severe form. Studies with subjects that are more compliant because they are on the higher end of the spectrum and can participate may produce data that can generalize to the entire spectrum. Research however, on brain tissue collected under previous diagnostic taxonomies may not be valid to the entire range represented by ASD.One gets a sense from recent provocative fi ndings in genetics, immunology and neurochemistry that the fi eld is much further along towards a comprehensive view of etiologies and ...

show abstract

“…Описан случай эффективности леветирацета-ма у пациента с хроническими двигательными тиками, роландической эпилепсией и СДВГ [31]. Сообщается также об уменьшении гиперактивности, импульсив-ности, лабильности настроения и агрессивности у де-тей с аутизмом при приеме леветирацетама [62]. С дру-гой стороны, в отечественной литературе описан случай развития СДВГ при введении леветирацетама [12]; при приеме данного препарата описаны случаи усиления возбудимости, раздражительности, колеба-ний настроения и периодической агрессивности.…”

Section: детской неврологииunclassified